Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44AI106283
Award Date
6/1/14
Completion Date
1/31/27
Dollars Obligated
$10M
Overview
Activity
16
Transactions
16
Subawards
3
Similar Awards
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Ceramedix Holding, LLC (JLZSJRJVKJ49)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, NY 10013, USA
Update #1
Update #2
DEVELOPMENT OF ANTI-CERAMIDE SCFV AS MITIGATOR OF THE RADIATION GI SYNDROME
Posted 4/25/18
5
1
2
3
4
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
NON-CLINICAL PHARMACOLOGY OF CX-01 - DEVELOPMENT OF RADIATION MEDICAL COUNTERMEASURES (MCM) HAS BECOME A NATIONAL SECURITY PRIORITY OWING TO SUCH THREATS AS RADIOLOGICAL DISPERSAL DEVICES (I.E., "DIRTY BOMB") AND NUCLEAR ACCIDENTS, WHICH MAY BE CAUSED BY EXTREME WEATHER (SUCH AS OCCURRED IN FUKUSHIMA, JAPAN IN 2011). RADIATION EXPOSURE CAN BE POTENTIALLY LETHAL VIA THE HEMATOPOIETIC-ACUTE RADIATION SYNDROME (H-ARS) AND THE GASTROINTESTINAL-ARS (GI-ARS). THE U.S. GOVERNMENT HAS COMMITTED TO SUPPORTING DEVELOPMENT OF MEDICAL COUNTERMEASURES (MCMS) TO MITIGATE MORBIDITY AND MORTALITY OF THESE RADIATION SYNDROMES. RE-PURPOSED LEUKEMIA DRUGS HAVE PROVEN USEFUL IN TREATMENT OF THE H-ARS IN PRECLINICAL MODELS, BUT THERE REMAINS NO EFFECTIVE MCM FOR GI-ARS. CERAMEDIX, INC. IS DEVELOPING A PIPELINE OF THERAPEUTIC CANDIDATES WITH THE GOAL OF PREVENTING AND MITIGATING ILLNESS DUE TO RADIATION EXPOSURE. OUR LEAD CANDIDATE, CX-01, IS AN ANTI-CERAMIDE SINGLE-CHAIN VARIABLE ANTIBODY FRAGMENT (SCFV) THAT BINDS CERAMIDE ON THE EXOCELLULAR LEAFLET OF THE PLASMA MEMBRANE OF RADIATION-INJURED ENDOTHELIAL CELLS IN THE GI TRACT AND IN OTHER ORGANS. BY BINDING CERAMIDE, CERAMIDE-RICH PLATFORMS ARE DISRUPTED, THEREBY PREVENTING CELLULAR DEATH. EXTENSIVE DATA IN MULTIPLE SPECIES, INCLUDING NON- HUMAN PRIMATES (NHPS), SHOW THAT DISRUPTING THE CERAMIDE SIGNALING PATHWAY PROTECTS AND MITIGATES THE GI- ARS. WE HAVE DEMONSTRATED DOSE-DEPENDENT EFFICACY IN NHPS AS WELL AS MORTALITY BENEFITS IN MICE. CX-01 MAY BE ADMINISTERED SUBCUTANEOUSLY, A CRITICAL ADVANTAGE DURING MASS CASUALTY EVENTS. CERAMEDIX' THERAPEUTICS MAY HAVE BROAD APPLICATION IN MULTIPLE ADDITIONAL DISEASES. CERAMIDE-RICH PLATFORM SIGNALING IS A UBIQUITOUS DAMAGE RESPONSE PATHWAY THAT DRIVES CELL INJURY AND DEATH IN RESPONSE TO DIVERSE DISEASE AND ENVIRONMENTAL STIMULI. CERAMEDIX HAS GENERATED SIGNIFICANT PRECLINICAL DATA SUPPORTING TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA. CERAMEDIX IS ALSO EXPLORING OTHER DISEASES INCLUDING DIABETIC NEPHROPATHY AND PULMONARY INJURY (FIBROSIS AND OTHER PULMONARY SYNDROMES). THE OVERALL GOAL OF THIS WORK IS TO VALIDATE THAT CX-01 DEMONSTRATES EQUIVALENT POTENCY AND EFFICACY AS A PRECURSOR NON-HUMANIZED SCFV MOLECULE. WE WILL PERFORM IN VITRO AND IN VIVO PHARMACOLOGICAL STUDIES TO SUPPORT CX-01 IND ACCEPTANCE. THE ABILITY TO PREVENT AND TREAT GI-ARS WOULD HAVE PROFOUND BENEFITS IN PROTECTING CIVILIANS AND DEFENSE PERSONNEL. THERE IS NO CURRENT TREATMENT FOR GI-ARS, PARTICULARLY ONE SUITABLE FOR FIELD ADMINISTRATION FOLLOWING A MASS CASUALTY EVENT. USG HAS PRIORITIZED THIS CRITICAL UNMET MEDICAL NEED. CX-01 REPRESENTS A MAJOR BREAKTHROUGH IN POTENTIAL TREATMENT OF THE LETHAL GI-ARS. CX-01 HAS THE POTENTIAL TO BECOME THE FIRST AND ONLY AVAILABLE TREATMENT FOR GI-ARS. SUCCESSFUL COMPLETION OF THIS WORK WILL ACCELERATE IND SUBMISSION AND CLINICAL EVALUATION OF CERAMEDIX' TRANSFORMATIVE THERAPEUTIC PLATFORM.
$0
11/13/25
Not listed
NON-CLINICAL PHARMACOLOGY OF CX-01 - DEVELOPMENT OF RADIATION MEDICAL COUNTERMEASURES (MCM) HAS BECOME A NATIONAL SECURITY PRIORITY OWING TO SUCH THREATS AS RADIOLOGICAL DISPERSAL DEVICES (I.E., "DIRTY BOMB") AND NUCLEAR ACCIDENTS, WHICH MAY BE CAUSED BY EXTREME WEATHER (SUCH AS OCCURRED IN FUKUSHIMA, JAPAN IN 2011). RADIATION EXPOSURE CAN BE POTENTIALLY LETHAL VIA THE HEMATOPOIETIC-ACUTE RADIATION SYNDROME (H-ARS) AND THE GASTROINTESTINAL-ARS (GI-ARS). THE U.S. GOVERNMENT HAS COMMITTED TO SUPPORTING DEVELOPMENT OF MEDICAL COUNTERMEASURES (MCMS) TO MITIGATE MORBIDITY AND MORTALITY OF THESE RADIATION SYNDROMES. RE-PURPOSED LEUKEMIA DRUGS HAVE PROVEN USEFUL IN TREATMENT OF THE H-ARS IN PRECLINICAL MODELS, BUT THERE REMAINS NO EFFECTIVE MCM FOR GI-ARS. CERAMEDIX, INC. IS DEVELOPING A PIPELINE OF THERAPEUTIC CANDIDATES WITH THE GOAL OF PREVENTING AND MITIGATING ILLNESS DUE TO RADIATION EXPOSURE. OUR LEAD CANDIDATE, CX-01, IS AN ANTI-CERAMIDE SINGLE-CHAIN VARIABLE ANTIBODY FRAGMENT (SCFV) THAT BINDS CERAMIDE ON THE EXOCELLULAR LEAFLET OF THE PLASMA MEMBRANE OF RADIATION-INJURED ENDOTHELIAL CELLS IN THE GI TRACT AND IN OTHER ORGANS. BY BINDING CERAMIDE, CERAMIDE-RICH PLATFORMS ARE DISRUPTED, THEREBY PREVENTING CELLULAR DEATH. EXTENSIVE DATA IN MULTIPLE SPECIES, INCLUDING NON- HUMAN PRIMATES (NHPS), SHOW THAT DISRUPTING THE CERAMIDE SIGNALING PATHWAY PROTECTS AND MITIGATES THE GI- ARS. WE HAVE DEMONSTRATED DOSE-DEPENDENT EFFICACY IN NHPS AS WELL AS MORTALITY BENEFITS IN MICE. CX-01 MAY BE ADMINISTERED SUBCUTANEOUSLY, A CRITICAL ADVANTAGE DURING MASS CASUALTY EVENTS. CERAMEDIX' THERAPEUTICS MAY HAVE BROAD APPLICATION IN MULTIPLE ADDITIONAL DISEASES. CERAMIDE-RICH PLATFORM SIGNALING IS A UBIQUITOUS DAMAGE RESPONSE PATHWAY THAT DRIVES CELL INJURY AND DEATH IN RESPONSE TO DIVERSE DISEASE AND ENVIRONMENTAL STIMULI. CERAMEDIX HAS GENERATED SIGNIFICANT PRECLINICAL DATA SUPPORTING TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA. CERAMEDIX IS ALSO EXPLORING OTHER DISEASES INCLUDING DIABETIC NEPHROPATHY AND PULMONARY INJURY (FIBROSIS AND OTHER PULMONARY SYNDROMES). THE OVERALL GOAL OF THIS WORK IS TO VALIDATE THAT CX-01 DEMONSTRATES EQUIVALENT POTENCY AND EFFICACY AS A PRECURSOR NON-HUMANIZED SCFV MOLECULE. WE WILL PERFORM IN VITRO AND IN VIVO PHARMACOLOGICAL STUDIES TO SUPPORT CX-01 IND ACCEPTANCE. THE ABILITY TO PREVENT AND TREAT GI-ARS WOULD HAVE PROFOUND BENEFITS IN PROTECTING CIVILIANS AND DEFENSE PERSONNEL. THERE IS NO CURRENT TREATMENT FOR GI-ARS, PARTICULARLY ONE SUITABLE FOR FIELD ADMINISTRATION FOLLOWING A MASS CASUALTY EVENT. USG HAS PRIORITIZED THIS CRITICAL UNMET MEDICAL NEED. CX-01 REPRESENTS A MAJOR BREAKTHROUGH IN POTENTIAL TREATMENT OF THE LETHAL GI-ARS. CX-01 HAS THE POTENTIAL TO BECOME THE FIRST AND ONLY AVAILABLE TREATMENT FOR GI-ARS. SUCCESSFUL COMPLETION OF THIS WORK WILL ACCELERATE IND SUBMISSION AND CLINICAL EVALUATION OF CERAMEDIX' TRANSFORMATIVE THERAPEUTIC PLATFORM.
$993.0k
1/3/25
Not listed
NON-CLINICAL PHARMACOLOGY OF CX-01 - DEVELOPMENT OF RADIATION MEDICAL COUNTERMEASURES (MCM) HAS BECOME A NATIONAL SECURITY PRIORITY OWING TO SUCH THREATS AS RADIOLOGICAL DISPERSAL DEVICES (I.E., "DIRTY BOMB") AND NUCLEAR ACCIDENTS, WHICH MAY BE CAUSED BY EXTREME WEATHER (SUCH AS OCCURRED IN FUKUSHIMA, JAPAN IN 2011). RADIATION EXPOSURE CAN BE POTENTIALLY LETHAL VIA THE HEMATOPOIETIC-ACUTE RADIATION SYNDROME (H-ARS) AND THE GASTROINTESTINAL-ARS (GI-ARS). THE U.S. GOVERNMENT HAS COMMITTED TO SUPPORTING DEVELOPMENT OF MEDICAL COUNTERMEASURES (MCMS) TO MITIGATE MORBIDITY AND MORTALITY OF THESE RADIATION SYNDROMES. RE-PURPOSED LEUKEMIA DRUGS HAVE PROVEN USEFUL IN TREATMENT OF THE H-ARS IN PRECLINICAL MODELS, BUT THERE REMAINS NO EFFECTIVE MCM FOR GI-ARS. CERAMEDIX, INC. IS DEVELOPING A PIPELINE OF THERAPEUTIC CANDIDATES WITH THE GOAL OF PREVENTING AND MITIGATING ILLNESS DUE TO RADIATION EXPOSURE. OUR LEAD CANDIDATE, CX-01, IS AN ANTI-CERAMIDE SINGLE-CHAIN VARIABLE ANTIBODY FRAGMENT (SCFV) THAT BINDS CERAMIDE ON THE EXOCELLULAR LEAFLET OF THE PLASMA MEMBRANE OF RADIATION-INJURED ENDOTHELIAL CELLS IN THE GI TRACT AND IN OTHER ORGANS. BY BINDING CERAMIDE, CERAMIDE-RICH PLATFORMS ARE DISRUPTED, THEREBY PREVENTING CELLULAR DEATH. EXTENSIVE DATA IN MULTIPLE SPECIES, INCLUDING NON- HUMAN PRIMATES (NHPS), SHOW THAT DISRUPTING THE CERAMIDE SIGNALING PATHWAY PROTECTS AND MITIGATES THE GI- ARS. WE HAVE DEMONSTRATED DOSE-DEPENDENT EFFICACY IN NHPS AS WELL AS MORTALITY BENEFITS IN MICE. CX-01 MAY BE ADMINISTERED SUBCUTANEOUSLY, A CRITICAL ADVANTAGE DURING MASS CASUALTY EVENTS. CERAMEDIX' THERAPEUTICS MAY HAVE BROAD APPLICATION IN MULTIPLE ADDITIONAL DISEASES. CERAMIDE-RICH PLATFORM SIGNALING IS A UBIQUITOUS DAMAGE RESPONSE PATHWAY THAT DRIVES CELL INJURY AND DEATH IN RESPONSE TO DIVERSE DISEASE AND ENVIRONMENTAL STIMULI. CERAMEDIX HAS GENERATED SIGNIFICANT PRECLINICAL DATA SUPPORTING TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA. CERAMEDIX IS ALSO EXPLORING OTHER DISEASES INCLUDING DIABETIC NEPHROPATHY AND PULMONARY INJURY (FIBROSIS AND OTHER PULMONARY SYNDROMES). THE OVERALL GOAL OF THIS WORK IS TO VALIDATE THAT CX-01 DEMONSTRATES EQUIVALENT POTENCY AND EFFICACY AS A PRECURSOR NON-HUMANIZED SCFV MOLECULE. WE WILL PERFORM IN VITRO AND IN VIVO PHARMACOLOGICAL STUDIES TO SUPPORT CX-01 IND ACCEPTANCE. THE ABILITY TO PREVENT AND TREAT GI-ARS WOULD HAVE PROFOUND BENEFITS IN PROTECTING CIVILIANS AND DEFENSE PERSONNEL. THERE IS NO CURRENT TREATMENT FOR GI-ARS, PARTICULARLY ONE SUITABLE FOR FIELD ADMINISTRATION FOLLOWING A MASS CASUALTY EVENT. USG HAS PRIORITIZED THIS CRITICAL UNMET MEDICAL NEED. CX-01 REPRESENTS A MAJOR BREAKTHROUGH IN POTENTIAL TREATMENT OF THE LETHAL GI-ARS. CX-01 HAS THE POTENTIAL TO BECOME THE FIRST AND ONLY AVAILABLE TREATMENT FOR GI-ARS. SUCCESSFUL COMPLETION OF THIS WORK WILL ACCELERATE IND SUBMISSION AND CLINICAL EVALUATION OF CERAMEDIX' TRANSFORMATIVE THERAPEUTIC PLATFORM.
$993.0k
1/3/25
Not listed
NON-CLINICAL PHARMACOLOGY OF CX-01 - DEVELOPMENT OF RADIATION MEDICAL COUNTERMEASURES (MCM) HAS BECOME A NATIONAL SECURITY PRIORITY OWING TO SUCH THREATS AS RADIOLOGICAL DISPERSAL DEVICES (I.E., "DIRTY BOMB") AND NUCLEAR ACCIDENTS, WHICH MAY BE CAUSED BY EXTREME WEATHER (SUCH AS OCCURRED IN FUKUSHIMA, JAPAN IN 2011). RADIATION EXPOSURE CAN BE POTENTIALLY LETHAL VIA THE HEMATOPOIETIC-ACUTE RADIATION SYNDROME (H-ARS) AND THE GASTROINTESTINAL-ARS (GI-ARS). THE U.S. GOVERNMENT HAS COMMITTED TO SUPPORTING DEVELOPMENT OF MEDICAL COUNTERMEASURES (MCMS) TO MITIGATE MORBIDITY AND MORTALITY OF THESE RADIATION SYNDROMES. RE-PURPOSED LEUKEMIA DRUGS HAVE PROVEN USEFUL IN TREATMENT OF THE H-ARS IN PRECLINICAL MODELS, BUT THERE REMAINS NO EFFECTIVE MCM FOR GI-ARS. CERAMEDIX, INC. IS DEVELOPING A PIPELINE OF THERAPEUTIC CANDIDATES WITH THE GOAL OF PREVENTING AND MITIGATING ILLNESS DUE TO RADIATION EXPOSURE. OUR LEAD CANDIDATE, CX-01, IS AN ANTI-CERAMIDE SINGLE-CHAIN VARIABLE ANTIBODY FRAGMENT (SCFV) THAT BINDS CERAMIDE ON THE EXOCELLULAR LEAFLET OF THE PLASMA MEMBRANE OF RADIATION-INJURED ENDOTHELIAL CELLS IN THE GI TRACT AND IN OTHER ORGANS. BY BINDING CERAMIDE, CERAMIDE-RICH PLATFORMS ARE DISRUPTED, THEREBY PREVENTING CELLULAR DEATH. EXTENSIVE DATA IN MULTIPLE SPECIES, INCLUDING NON- HUMAN PRIMATES (NHPS), SHOW THAT DISRUPTING THE CERAMIDE SIGNALING PATHWAY PROTECTS AND MITIGATES THE GI- ARS. WE HAVE DEMONSTRATED DOSE-DEPENDENT EFFICACY IN NHPS AS WELL AS MORTALITY BENEFITS IN MICE. CX-01 MAY BE ADMINISTERED SUBCUTANEOUSLY, A CRITICAL ADVANTAGE DURING MASS CASUALTY EVENTS. CERAMEDIX' THERAPEUTICS MAY HAVE BROAD APPLICATION IN MULTIPLE ADDITIONAL DISEASES. CERAMIDE-RICH PLATFORM SIGNALING IS A UBIQUITOUS DAMAGE RESPONSE PATHWAY THAT DRIVES CELL INJURY AND DEATH IN RESPONSE TO DIVERSE DISEASE AND ENVIRONMENTAL STIMULI. CERAMEDIX HAS GENERATED SIGNIFICANT PRECLINICAL DATA SUPPORTING TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA. CERAMEDIX IS ALSO EXPLORING OTHER DISEASES INCLUDING DIABETIC NEPHROPATHY AND PULMONARY INJURY (FIBROSIS AND OTHER PULMONARY SYNDROMES). THE OVERALL GOAL OF THIS WORK IS TO VALIDATE THAT CX-01 DEMONSTRATES EQUIVALENT POTENCY AND EFFICACY AS A PRECURSOR NON-HUMANIZED SCFV MOLECULE. WE WILL PERFORM IN VITRO AND IN VIVO PHARMACOLOGICAL STUDIES TO SUPPORT CX-01 IND ACCEPTANCE. THE ABILITY TO PREVENT AND TREAT GI-ARS WOULD HAVE PROFOUND BENEFITS IN PROTECTING CIVILIANS AND DEFENSE PERSONNEL. THERE IS NO CURRENT TREATMENT FOR GI-ARS, PARTICULARLY ONE SUITABLE FOR FIELD ADMINISTRATION FOLLOWING A MASS CASUALTY EVENT. USG HAS PRIORITIZED THIS CRITICAL UNMET MEDICAL NEED. CX-01 REPRESENTS A MAJOR BREAKTHROUGH IN POTENTIAL TREATMENT OF THE LETHAL GI-ARS. CX-01 HAS THE POTENTIAL TO BECOME THE FIRST AND ONLY AVAILABLE TREATMENT FOR GI-ARS. SUCCESSFUL COMPLETION OF THIS WORK WILL ACCELERATE IND SUBMISSION AND CLINICAL EVALUATION OF CERAMEDIX' TRANSFORMATIVE THERAPEUTIC PLATFORM.
$1.0m
2/5/24
Not listed
NON-CLINICAL PHARMACOLOGY OF CX-01 - DEVELOPMENT OF RADIATION MEDICAL COUNTERMEASURES (MCM) HAS BECOME A NATIONAL SECURITY PRIORITY OWING TO SUCH THREATS AS RADIOLOGICAL DISPERSAL DEVICES (I.E., "DIRTY BOMB") AND NUCLEAR ACCIDENTS, WHICH MAY BE CAUSED BY EXTREME WEATHER (SUCH AS OCCURRED IN FUKUSHIMA, JAPAN IN 2011). RADIATION EXPOSURE CAN BE POTENTIALLY LETHAL VIA THE HEMATOPOIETIC-ACUTE RADIATION SYNDROME (H-ARS) AND THE GASTROINTESTINAL-ARS (GI-ARS). THE U.S. GOVERNMENT HAS COMMITTED TO SUPPORTING DEVELOPMENT OF MEDICAL COUNTERMEASURES (MCMS) TO MITIGATE MORBIDITY AND MORTALITY OF THESE RADIATION SYNDROMES. RE-PURPOSED LEUKEMIA DRUGS HAVE PROVEN USEFUL IN TREATMENT OF THE H-ARS IN PRECLINICAL MODELS, BUT THERE REMAINS NO EFFECTIVE MCM FOR GI-ARS. CERAMEDIX, INC. IS DEVELOPING A PIPELINE OF THERAPEUTIC CANDIDATES WITH THE GOAL OF PREVENTING AND MITIGATING ILLNESS DUE TO RADIATION EXPOSURE. OUR LEAD CANDIDATE, CX-01, IS AN ANTI-CERAMIDE SINGLE-CHAIN VARIABLE ANTIBODY FRAGMENT (SCFV) THAT BINDS CERAMIDE ON THE EXOCELLULAR LEAFLET OF THE PLASMA MEMBRANE OF RADIATION-INJURED ENDOTHELIAL CELLS IN THE GI TRACT AND IN OTHER ORGANS. BY BINDING CERAMIDE, CERAMIDE-RICH PLATFORMS ARE DISRUPTED, THEREBY PREVENTING CELLULAR DEATH. EXTENSIVE DATA IN MULTIPLE SPECIES, INCLUDING NON- HUMAN PRIMATES (NHPS), SHOW THAT DISRUPTING THE CERAMIDE SIGNALING PATHWAY PROTECTS AND MITIGATES THE GI- ARS. WE HAVE DEMONSTRATED DOSE-DEPENDENT EFFICACY IN NHPS AS WELL AS MORTALITY BENEFITS IN MICE. CX-01 MAY BE ADMINISTERED SUBCUTANEOUSLY, A CRITICAL ADVANTAGE DURING MASS CASUALTY EVENTS. CERAMEDIX' THERAPEUTICS MAY HAVE BROAD APPLICATION IN MULTIPLE ADDITIONAL DISEASES. CERAMIDE-RICH PLATFORM SIGNALING IS A UBIQUITOUS DAMAGE RESPONSE PATHWAY THAT DRIVES CELL INJURY AND DEATH IN RESPONSE TO DIVERSE DISEASE AND ENVIRONMENTAL STIMULI. CERAMEDIX HAS GENERATED SIGNIFICANT PRECLINICAL DATA SUPPORTING TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA. CERAMEDIX IS ALSO EXPLORING OTHER DISEASES INCLUDING DIABETIC NEPHROPATHY AND PULMONARY INJURY (FIBROSIS AND OTHER PULMONARY SYNDROMES). THE OVERALL GOAL OF THIS WORK IS TO VALIDATE THAT CX-01 DEMONSTRATES EQUIVALENT POTENCY AND EFFICACY AS A PRECURSOR NON-HUMANIZED SCFV MOLECULE. WE WILL PERFORM IN VITRO AND IN VIVO PHARMACOLOGICAL STUDIES TO SUPPORT CX-01 IND ACCEPTANCE. THE ABILITY TO PREVENT AND TREAT GI-ARS WOULD HAVE PROFOUND BENEFITS IN PROTECTING CIVILIANS AND DEFENSE PERSONNEL. THERE IS NO CURRENT TREATMENT FOR GI-ARS, PARTICULARLY ONE SUITABLE FOR FIELD ADMINISTRATION FOLLOWING A MASS CASUALTY EVENT. USG HAS PRIORITIZED THIS CRITICAL UNMET MEDICAL NEED. CX-01 REPRESENTS A MAJOR BREAKTHROUGH IN POTENTIAL TREATMENT OF THE LETHAL GI-ARS. CX-01 HAS THE POTENTIAL TO BECOME THE FIRST AND ONLY AVAILABLE TREATMENT FOR GI-ARS. SUCCESSFUL COMPLETION OF THIS WORK WILL ACCELERATE IND SUBMISSION AND CLINICAL EVALUATION OF CERAMEDIX' TRANSFORMATIVE THERAPEUTIC PLATFORM.
$1.0m
2/5/24
5
1
GrantNumber
Description
Subgrantee
Prime Award
Dollars Obligated
Updated At
001S
Develop a partial body irradiation mouse model. Use the newly developed model to evaluate efficacy of a lead anti-ceramide compound.
Sloan-Kettering Institute For Cancer Research
Project Grant R44AI106283
$424.8k
3/20/25
001S
Develop a partial body irradiation mouse model. Use the newly developed model to evaluate efficacy of a lead anti-ceramide compound.
Sloan-Kettering Institute For Cancer Research
Project Grant R44AI106283
$424.8k
2/10/25
001S
Develop a partial body irradiation mouse model. Use the newly developed model to evaluate efficacy of a lead anti-ceramide compound.
Sloan-Kettering Institute For Cancer Research
Project Grant R44AI106283
$424.8k
2/10/25